rosiglitazone
rosiglitazone: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
rosiglitazone evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could rosiglitazone → TEVA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) Reported 2017-05-19 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Primary endpoint: Metformin Cmax geometric mean ratio
Frequently asked questions
Which companies have sourced relationships with rosiglitazone?
rosiglitazone has dated SEC/FDA relationship records for Teva Pharmaceutical Industries Limited.
How many clinical trials involve rosiglitazone?
BioSniper tracks 1 clinical trial involving rosiglitazone.
What is rosiglitazone's latest FDA decision?
The most recent tracked FDA decision for rosiglitazone is Approval, dated May 19, 2017.